Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Ovarian Cancer

Presenters

Ana Maria Catana

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

A.M. Catana1, P. Just1, G. De Rauglaudre2, N. Raban3, A. Chevalier4, G. Ferron5, M. Kaminsky-Forrett6, I.L. Ray-Coquard7, S. Hamizi8, P. Combe9, S. Abadie Lacourtoisie10, F. Joly Lobbedez11, J. Meunier12, C. Lebreton13, J. Alexandre14, P. Follana15, J. Lotz16, F. Del Piano17, O. Colomban7, B. You18

Author affiliations

  • 1 Pathology, Hopital Timone, 75679 - Marseille/FR
  • 2 Vaucluse, Institut Sainte-Catherine, 84918 - Avignon, Cedex/FR
  • 3 Department Of Gynecological Cancer, CHU Poitiers - Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 4 Department Of Gynecological Cancer, Centre Oscar Lambret, 59020 - Lille/FR
  • 5 Department Of Gynecological Cancer, IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, 31059 - Toulouse/FR
  • 6 Medical Oncology Department, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre-lès-Nancy/FR
  • 7 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 8 Oncology Department, CHU de Saint Etienne, 42270 - Saint-Priest-en-Jarez/FR
  • 9 Medical Oncology Department, Centre d'Oncologie et Radiothérapie 37, Chambray-lès-Tours/FR
  • 10 Medical Oncology Department, Institut de Cancérologie de l’Ouest - ICO - Site Paul Papin, Angers/FR
  • 11 Gynecological Medical Oncology Department, Institut de Cancérologie de l’Ouest - ICO - Site Paul Papin, Angers/FR
  • 12 Medical Oncology Department, CHR - Centre Hospitalier Régional d'Orléans - La Source, 45100 - Orleans/FR
  • 13 Medical Oncology Department, Institut Bergonié, 33000 - Bordeaux/FR
  • 14 Medical Oncology Department, Hopital Cochin - Site Port-Royal AP-HP, 75014 - Paris/FR
  • 15 Medical Oncology, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 16 Medical Oncology, Hopital Tenon AP-HP, 75970 - Paris, Cedex/FR
  • 17 Gynecological Surgery, Hôpitaux du Léman, 74200 - Thonon-les-Bains/FR
  • 18 Oncology Department, HCL, 69495 - Pierre-Bénite/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 793P

Background

The modeled CA-125 longitudinal kinetic parameter KELIMTM during 1st-line chemotherapy is as a pragmatic indicator of the tumor primary chemosensivitiy. However, the links between KELIMTM and the beneath chemotherapy-induced tumor biological effects had to be explored. We studied the links between KELIMTM values and pathological response, and changes in TILs, in ovarian cancer patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery (IDS).

Methods

In the randomized phase II trial CHIVA (NCT01583322), 188 patients were treated with NACT carboplatin-paclitaxel +/- nintedanib, +/- IDS. Patient KELIMs were previously calculated. The pathological response was assessed with the Chemotherapy Response Score on the omentum (CRS 1-3), and with an enriched pathological response pR score based on the available tumor tissue block when omentum was lacking (pRS 1-3), obtained after NACT. Changes in stromal TILs (sTILs, % of the stromal surface on lymphocytes) and intra-epithelial TILs (ieTILs, qualitative appreciation, 0-2) in baseline tissue and after NACT were analyzed.

Results

A strong association was found between patient KELIMTM value and the omentum CRS after NACT (n=67; median KELIMTM, 0.71 for CRS-1; 1.26 for CRS-2; 1.66 for CRS-3; P<0.01). Consistent, a correlation was observed between KELIM and tumor pRS (n=103; median KELIMTM, 0.73 for pRS-1; 1.25 for pRS-2; 1.61 for pRS-3; P <0.01). At baseline before NACT, no relationships between KELIMTM and TILs were found. After NACT, a significant association was observed between higher patient KELIMTM values and higher intra-epithelial TILs infiltrate after NACT (n=99; median KELIM, 0.88 for ieTILs score 0-1; vs 1.26 for ieTILs score 2; P = 0.03).

Conclusions

High consistency was found between patients KELIMTM and the pathological response after neo-adjuvant chemotherapy, assessed with the omentum CRS score, or the larger tumor pRS score. Omentum may not necessarily needed to assess the pathological response. Intra-epithelial TILs change after NACT was strongly associated with KELIMTM-assessed chemosensitivity, thereby opening hypotheses about mechanisms of platinum-sensitivity.

Clinical trial identification

NCT01583322.

Editorial acknowledgement

Legal entity responsible for the study

ARCAGY-GINECO (Paris, France).

Funding

Hospital de la Timone (Marseille, France) and Université Claude Bernard Lyon 1 (Lyon, France).

Disclosure

G. Ferron: Financial Interests, Advisory Board: Olympus, AstraZeneca, MSD, Clovis Oncology, Rand-biotech; Financial Interests, Other, Honoraria: Olympus, AstraZeneca, MSD, Roche, Clovis Oncology, EISAI, GSK Tesaro, RanD Biotech; Financial Interests, Other, R&D contract: Olympus; Financial Interests, Other, Educational courses: Olympus, Rand-biotech; Financial Interests, Funding, Congress Funding: AstraZeneca, MSD, Roche, PharmaMar, EISAI, GSK Tesaro. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmune, Eisai, SUTRO, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Principal Investigator: PAOLA1; Non-Financial Interests, Other, President: GINECO. P. Combe: Financial Interests, Advisory Board: AstraZeneca, BMS, MSD, EISAI, SANOFI, Novartis, Daiichi Sankyo, Clovis Oncology, GSK, Amgen; Financial Interests, Other, Investigator in clinical trial: MSD, Novartis, AstraZeneca, BMS. F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, Ipsen, BMS, Bayer, Eisai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Coordinating PI: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Other, Travel: MSD, GSK. C. Lebreton: Financial Interests, Personal, Advisory Board: GSK, MSD, Eisai, Clovis Oncology. J. Alexandre: Financial Interests, Personal, Advisory Board: Eisai, MSD, GSK, Janssen, Pfizer; Financial Interests, Personal, Invited Speaker: Eisai, MSD, AstraZeneca, GSK, Novartis; Financial Interests, Institutional, Research Grant: Janssen, GSK, MSD; Financial Interests, Institutional, Local PI: MSD, Eisai, Agenus, GSK, Immunogen, Incyte. P. Follana: Financial Interests, Personal, Invited Speaker: GSK, Eisai, MSD; Financial Interests, Personal, Advisory Board: Clovis, AZ, Novartis; Financial Interests, Personal, Other, Congress invitation: Gilead. B. You: Financial Interests, Personal, Advisory Board: AZ, MSD, Roche, GSK, Eisai, Seagen, Bayer, Novartis, Amgen, Clovis, BMS, Myriad, Menarini, Gilead. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.